Asthma, Allergic Completed Phase 4 Trials for Omalizumab (DB00043)

Also known as: Atopic Asthma / Allergic Asthma / Asthma extrinsic / Extrinsic asthma / Asthma / Asthma, unspecified / Asthma bronchial / Asthma NOS / Asthmatic / Br. asthma / Bronchitic asthma

DBCOND0047182 (Asthma, Allergic)Completed4 IdentifierTitlePurposeDrugs
NCT00283504A Description of Inflammatory Cell Types In Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE TherapyDiagnostic
NCT02023151Predicting the Clinical Response to Omalizumab With Anti-Immunoglobulin E (IgE) Ab Response or Syk Expression in BasophilsTreatment
NCT00267202Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic AsthmaTreatment
NCT00670930Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonistsTreatment
NCT00813748Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair Dosing
NCT01125748A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term TherapyTreatment